|1.||Nicolau, David P: 15 articles (11/2015 - 06/2004)|
|2.||Kuti, Joseph L: 9 articles (11/2014 - 07/2005)|
|3.||Bonomo, Robert A: 5 articles (12/2015 - 10/2005)|
|4.||Crandon, Jared L: 5 articles (11/2015 - 04/2009)|
|5.||Roberts, Jason A: 5 articles (10/2015 - 02/2007)|
|6.||Lipman, Jeffrey: 5 articles (12/2012 - 02/2007)|
|7.||Jones, Ronald N: 5 articles (04/2009 - 03/2002)|
|8.||Tam, Vincent H: 4 articles (05/2015 - 09/2002)|
|9.||Tamura, Kazuo: 4 articles (01/2015 - 08/2006)|
|10.||McKinnon, Peggy S: 4 articles (08/2009 - 09/2002)|
06/01/2008 - "Cefepime therapy using a 250 mg/m(2) dose administered every 12 h is adequate to achieve plasma concentrations greater than 8 mug/mL during more than 60% of the dosing interval and is expected to be effective in the treatment of bloodstream infections caused by most gram negative organisms in newborn infants. "
01/01/2000 - "The excellent activity against most Gram negative and Gram positive pathogens suggests that cefepime may be useful in the treatment of serious infections in the described patient population."
01/01/1989 - "The high in vitro activity of cefepime was reflected in its in vivo efficacy against experimental infections in normal and immuno-suppressed mice. "
03/01/2001 - "Treatment with cefepime 50 mg/kg/ dose administered every 8 to 12 h produced a satisfactory clinical response (clinical signs of infection resolved or improved with no evidence of recurrent infection at posttreatment follow-up) in 88 to 100% of patients, comparable with comparator therapy. "
02/01/2008 - "The T>MIC values (8 h) of cefepime suggested that this agent is clinically effective in the treatment of various infections."
05/01/2008 - "In conclusion, fixed dose combination of Cefepime and Amakacin was more effective in the treatment of nosocomial pneumonia than Cefepime alone."
01/01/1999 - "Our data suggest that cefepime was safe and effective for treatment of severe pneumonia in hospitalized patients."
01/01/2012 - "Patient's pneumonia improved with treatment with cefepime. "
01/01/2013 - "The results of this study show that cefepime is not a reasonable choice for empirical treatment of nosocomial pneumonia and VAP."
01/01/2010 - "We examined these issues in a prospective non-interventional study of 21 consecutive intensive care unit (ICU) adult patients treated with cefepime for nosocomial pneumonia. "
08/01/1997 - "Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients."
11/01/1993 - "In a pilot study, we evaluated the efficacy and the safety of cefepime, a new cephalosporin with extended-spectrum activity against both Gram-positive and Gram-negative bacteria, as empirical monotherapy for 108 febrile episodes in 84 granulocytopenic cancer patients. "
06/01/2012 - "Cefepime efficacy for treatment of febrile neutropenia (FN) in cancer adult patients is a controversial issue. "
01/01/2002 - "The aim of this study was to prospectively evaluate the effectiveness of cefepime monotherapy in the treatment of cancer patients with febrile granulocytopenia (< 1000 leukocytes/muL and/or < 500 neutrophils/muL). "
12/01/2006 - "Cefepime monotherapy is a safe and feasible option for treatment of childhood cancer patients with febrile neutropenia."
08/01/1999 - "It is concluded that cefepime monotherapy appeared both safe and effective as empirical therapy in patients with febrile neutropenia."
08/15/2010 - "A sensitivity analysis based solely on the 24 febrile neutropenia trials did not show a statistically significant increase in mortality with cefepime use (ARD per 1000 population, 9.67; 95% CI, -2.87 to 22.21). "
08/01/1999 - "The purpose of this phase II trial was to evaluate the efficacy and safety of cefepime monotherapy in patients with neutropenia expected to last more than 7 days. "
09/01/2015 - "While guidelines recommend empirical cefepime therapy in febrile neutropenia, the mortality benefit of cefepime has been controversial. "
06/01/2012 - "To describe the demographic characteristics and general mortality of patients suffering from febrile neutropenia treated with cefepime in a fourth-level Latin American hospital. "
|5.||Bacterial Infections (Bacterial Infection)
10/01/2002 - "The safety and efficacy of cefepime empiric monotherapy compared with standard broad-spectrum combination therapy for hospitalized adult patients with moderate to severe community-acquired bacterial infections were evaluated. "
11/01/1993 - "We evaluated the efficacy of cefepime 1 g bd as treatment for acute, moderately severe bacterial infection in 239 hospitalized patients (mean age 60 years). "
03/01/2001 - "Four clinical trials of cefepime for the treatment of serious bacterial infections enrolled 259 children with LRTI. "
11/01/1993 - "A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections."
01/01/2014 - "Cefepime may be given intramuscularly at 12 h intervals to combat susceptible bacterial infections. "
|10.||Cephalosporins (Cephalosporin Antibiotics)
|1.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|4.||Drug Therapy (Chemotherapy)
|5.||Renal Replacement Therapy (Therapies, Renal Replacement)